SCHEMBL949944

SCHEMBL949944

CCC(SC)c1ccccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 7/20 0.47
KCNH2 Q12809 1/20 0.47
TSHR P16473 1/20 0.46
KCNE1 P15382 2/20 0.45
CYP2D6 P10635 1/20 0.45
CYP1A2 P05177 2/20 0.42
ALDH1A1 P00352 1/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 1/20 0.42
CHRM2 P08172 2/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KCNJ5 P48544 1/20 0.37
KCNJ3 P48549 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15196339 0.83 KCNA5 (0.46) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL10297723 0.83 TSHR (0.44) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL12125558 0.81 KCNA5 (0.45) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL21535612 0.80 TSHR (0.42) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL28918171 0.79 SMN1; SMN2 (0.46) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL8203878 0.78 KCNA5 (0.43) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL178205 0.76 KCNA5 (0.50) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL29520435 0.75 TSHR (0.62) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL65284 0.75 TSHR (0.62) KCNA5KCNH2TSHRKCNE1CYP2D6
SCHEMBL3910230 0.75 TSHR (0.62) KCNA5KCNH2TSHRKCNE1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883828-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2014-11-11 US disclosed
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2013-03-14 US disclosed
US-8354540-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2013-01-15 US disclosed
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2011-11-17 US disclosed
US-8022223-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20110021483-A1 Platinum (IV) Complexes PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2011-01-27 US disclosed
EP-2170913-A1 PLATINUM (IV) COMPLEXES Platco Technologies (Proprietary) Limited (ZA) 2010-04-07 EP disclosed
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-06-18 US disclosed
WO-2008155727-A1 PLATINUM (IV) COMPLEXES PLATCO TECHNOLOGIES (PROPRIETARY) LIMITED (ZA) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, PRKCSH KCNA5 449/4885KCNH2 472/4885TSHR 3803/4885
US-20110021483-A1 Platinum (IV) Complexes OTC, OAT, SLC25A11 KCNA5 4014/4885KCNH2 4031/4885TSHR 3780/4885
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 KCNA5 1148/4885KCNH2 982/4885TSHR 4515/4885
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 KCNA5 1148/4885KCNH2 982/4885TSHR 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.